Tamoxifen
- Generic Name
- Tamoxifen
- Brand Names
- Soltamox
- Drug Type
- Small Molecule
- Chemical Formula
- C26H29NO
- CAS Number
- 10540-29-1
- Unique Ingredient Identifier
- 094ZI81Y45
- Background
Tamoxifen is a non-steroidal antiestrogen used to treat estrogen receptor positive breast cancers as well as prevent the incidence of breast cancer in high risk populations. Tamoxifen is used alone or as an adjuvant in these treatments. Tamoxifen may no longer be the preferred treatment for these types of cancers as patients generally have better survival, s...
- Indication
Tamoxifen is indicated to treat estrogen receptor positive metastatic breast cancer in adults, as an adjuvant in the treatment of early stage estrogen receptor positive breast cancer in adults, to reduce the risk of invasive breast cancer after surgery and radiation in adult women with ductal carcinoma in situ.
- Associated Conditions
- Breast Cancer, Contralateral Breast Cancer, Desmoid Tumor, Early Stage Estrogen Receptor (ER) Positive Breast Cancer, Gynecomastia, Invasive Breast Cancer, Ovarian Cancer, Puberty, Precocious, Metastatic Estrogen Receptor Positive Breast Cancer
- Associated Therapies
- Ovulation induction therapy
Tamoxifen Prediction Study in Patients With ER+ Breast Cancer
- First Posted Date
- 2022-09-01
- Last Posted Date
- 2023-11-01
- Lead Sponsor
- Erasmus Medical Center
- Target Recruit Count
- 100
- Registration Number
- NCT05525481
- Locations
- ๐ณ๐ฑ
Erasmus MC, Rotterdam, Zuid-Holland, Netherlands
A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2022-08-24
- Last Posted Date
- 2024-12-09
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 6000
- Registration Number
- NCT05514054
- Locations
- ๐บ๐ธ
Summit Cancer Care, PC, Savannah, Georgia, United States
๐บ๐ธSaint Alphonsus Regional Medical Center, Boise, Idaho, United States
๐บ๐ธStaten Island University Hospital, Staten Island, New York, United States
Elacestrant for Treating ER+/HER2- Breast Cancer Patients With ctDNA Relapse (TREAT ctDNA)
- First Posted Date
- 2022-08-23
- Last Posted Date
- 2024-01-24
- Target Recruit Count
- 220
- Registration Number
- NCT05512364
- Locations
- ๐ง๐ช
Institut Jules Bordet, Anderlecht, Belgium
๐ง๐ชPole Hospitalier Jolimont - Hopital Jolimont, Haine-Saint-Paul, Belgium
๐ง๐ชCHU Site Sainte-Elisabeth-UCL Namur, Namur, Belgium
CYP2D6 Genotypes and Breast Cancer Clinical Outcomes in the Indonesian Population
- First Posted Date
- 2022-08-15
- Last Posted Date
- 2022-08-19
- Lead Sponsor
- Nalagenetics Pte Ltd
- Target Recruit Count
- 150
- Registration Number
- NCT05501158
- Locations
- ๐ฎ๐ฉ
MRCCC Siloam Hospitals Semanggi, Jakarta, DKI Jakarta, Indonesia
ETHAN - ET for Male BC
- First Posted Date
- 2022-08-15
- Last Posted Date
- 2024-12-18
- Lead Sponsor
- Jose Pablo Leone
- Target Recruit Count
- 60
- Registration Number
- NCT05501704
- Locations
- ๐บ๐ธ
Georgetown University Medical Center, Washington, District of Columbia, United States
๐บ๐ธDana Farber Cancer Institute, Boston, Massachusetts, United States
๐บ๐ธMayo Clinic, Rochester, Minnesota, United States
Study of Intravaginal Tamoxifen in PostMenopausal Women With VVA
- First Posted Date
- 2022-05-18
- Last Posted Date
- 2024-10-21
- Lead Sponsor
- Darรฉ Bioscience, Inc.
- Target Recruit Count
- 17
- Registration Number
- NCT05378269
- Locations
- ๐ฆ๐บ
Keogh Institute for Medical Research, Nedlands, Western Australia, Australia
๐ฆ๐บPARC Clinical Research, Adelaide, Southern Australia, Australia
A Study Evaluating the Efficacy and Safety of Giredestrant Plus Everolimus Compared With the Physician's Choice of Endocrine Therapy Plus Everolimus in Participants With Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer (evERA Breast Cancer)
- First Posted Date
- 2022-04-01
- Last Posted Date
- 2024-10-16
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 320
- Registration Number
- NCT05306340
- Locations
- ๐บ๐ธ
Alabama Oncology - Bruno Cancer Center, Birmingham, Alabama, United States
๐บ๐ธAlaska Oncology and Hematology, Anchorage, Alaska, United States
๐บ๐ธThe Dignity Health Cancer Institute, Phoenix, Arizona, United States
Roll-over Study to Allow Continued Access to Ribociclib
- Conditions
- Interventions
- First Posted Date
- 2021-12-17
- Last Posted Date
- 2024-10-14
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 137
- Registration Number
- NCT05161195
- Locations
- ๐บ๐ธ
Poudre Valley Hospital, Fort Collins, Colorado, United States
๐บ๐ธIronwood Cancer and Research Centers, Chandler, Arizona, United States
๐บ๐ธHighlands Oncology Group, Fayetteville, Arkansas, United States
Tamoxifen and SUBA-Itraconzole Combination Testing in Ovarian Cancer
- First Posted Date
- 2021-12-14
- Last Posted Date
- 2022-12-21
- Lead Sponsor
- Anthony Joshua, FRACP
- Target Recruit Count
- 44
- Registration Number
- NCT05156892
- Locations
- ๐ฆ๐บ
Kinghorn Cancer Centre, St. Vincent's Hospital, Sydney, New South Wales, Australia
Neoadjuvant Endocrine Therapy in ER-positive, HER2-negative Early Stage Breast Cancer
- First Posted Date
- 2021-12-09
- Last Posted Date
- 2024-01-30
- Lead Sponsor
- Veronica Morgan Jones
- Target Recruit Count
- 70
- Registration Number
- NCT05150652
- Locations
- ๐บ๐ธ
University of Kentucky Markey Cancer Center, Lexington, Kentucky, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.